Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Vascular diseases

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44339   clinical trials with a EudraCT protocol, of which   7369   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    1,302 result(s) found for: Vascular diseases. Displaying page 9 of 66.
    «« First « Previous 5  6  7  8  9  10  11  12  13  Next» Last»»
    EudraCT Number: 2008-004016-12 Sponsor Protocol Number: Start Date*: 2009-01-21
    Sponsor Name:Lijf en Leven
    Full Title: Clopidogrel for the prevention of late cardiac events in patients with asymptomatic perioperative acute coronary syndrome.
    Medical condition: Study target patients are those with peripheral arterial disease who underwent a major vascular surgery and develop asymptomatic troponine-elevation. These patients are randomised for treatment wit...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10034638 Peripheral vascular disorders NEC HLT
    9.1 10018106 Generalized arterial disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2020-001236-10 Sponsor Protocol Number: COVID-19 Start Date*: 2020-03-31
    Sponsor Name:Amsterdam UMC
    Full Title: COUNTER-COVID - Oral imatinib to prevent pulmonary vascular leak in Covid19 – a randomized, double --blind, placebo controlled, clinical trial in patients with severe Covid19 disease’
    Medical condition: Covid19 is characterized by hypoxemic respiratory failure, caused by extensive vascular leak and pulmonary edema early in the course of disease.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2007-004448-60 Sponsor Protocol Number: 0653A-128 Start Date*: 2007-11-13
    Sponsor Name:Merck & Co., Inc.
    Full Title: A Multicenter, Randomized, Double-Blind, Parallel Arm, 12-Week Study to Evaluate the Efficacy and Safety of Ezetimibe/Simvastatin Combination Tablet Versus Atorvastatin in Elderly Patients With Hyp...
    Medical condition: Hypercholesterolemia
    Disease: Version SOC Term Classification Code Term Level
    9.1 10020604 Hypercholesterolemia LLT
    Population Age: Elderly Gender: Male, Female
    Trial protocol: LT (Completed) IE (Completed) FI (Completed) BE (Completed) DK (Completed) DE (Completed) IT (Completed) AT (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2006-002942-12 Sponsor Protocol Number: P04737 Start Date*: 2007-10-22
    Sponsor Name:Schering-Plough Research Institute
    Full Title: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of SCH 530348 in Addition to Standard of Care in Subjects With a History of Atherosclerotic Dis...
    Medical condition: Documented coronary artery disease, postischemic cerebrovascular disease or peripheral artery disease.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10043634 Thrombosis prophylaxis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) DK (Completed) NL (Completed) SE (Completed) PT (Completed) FI (Completed) CZ (Completed) GB (Completed) BE (Completed) IT (Completed) ES (Completed) AT (Completed) DE (Completed) PL (Completed) HU (Completed)
    Trial results: View results
    EudraCT Number: 2012-000061-21 Sponsor Protocol Number: I1V-MC-EIAN Start Date*: 2012-10-25
    Sponsor Name:Eli Lilly and Company
    Full Title: Protocol I1V-MC-EIAN Assessment of Clinical Effects of Cholesteryl Ester Transfer Protein Inhibition with Evacetrapib in Patients at a High-Risk for Vascular Outcomes - the ACCELERATE Study
    Medical condition: High Risk Vascular Disease (HRVD)
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004866 10067825 Peripheral arterial disease LLT
    18.1 10007541 - Cardiac disorders 10051592 Acute coronary syndrome PT
    18.1 10007541 - Cardiac disorders 10011078 Coronary artery disease PT
    18.1 100000004852 10003602 Atherosclerosis cerebral LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) SK (Prematurely Ended) EE (Prematurely Ended) DE (Prematurely Ended) BE (Prematurely Ended) SE (Prematurely Ended) HU (Prematurely Ended) AT (Completed) ES (Prematurely Ended) LT (Prematurely Ended) DK (Prematurely Ended) IT (Prematurely Ended) CZ (Prematurely Ended) PL (Prematurely Ended) BG (Prematurely Ended) NL (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2018-001603-37 Sponsor Protocol Number: AC-055G203 Start Date*: 2019-07-16
    Sponsor Name:ACTELION Pharmaceuticals Ltd
    Full Title: A long-term, multicenter, single-arm, open-label extension of the SERENADE study, to assess the safety and efficacy of macitentan in subjects with heart failure with preserved ejection fraction and...
    Medical condition: Heart failure with preserved ejection fraction and pulmonary vascular disease
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004849 10076396 Heart failure with preserved ejection fraction LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BG (Prematurely Ended) DE (Prematurely Ended) HU (Prematurely Ended) DK (Prematurely Ended) SE (Prematurely Ended) RO (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2005-002457-41 Sponsor Protocol Number: 150-CL-008 Start Date*: 2006-05-15
    Sponsor Name:Astellas Pharma Europe B.V.
    Full Title: Direct Factor Xa inhibitor YM150 for prevention of venous thromboembolism in patients undergoing elective total hip replacement. A double blind, parallel, dose-finding study in comparison with open...
    Medical condition: Elective primary hip replacement surgery
    Disease: Version SOC Term Classification Code Term Level
    10020096
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed) CZ (Completed) SK (Completed) DE (Completed) SE (Completed) NO (Completed) FI (Completed) PT (Completed) GR (Completed) IT (Completed) LT (Completed) EE (Prematurely Ended) LV (Completed)
    Trial results: View results
    EudraCT Number: 2016-000571-25 Sponsor Protocol Number: HTA-OBESIDAD-2016 Start Date*: 2016-06-16
    Sponsor Name:Fundació Clinic per a la Recerca Biomèdica
    Full Title: Seeking the ideal anti-hypertensive therapy in obesity-related hypertension. An open-label, single center, randomized clinical trial.
    Medical condition: obesity linked hypertension
    Disease: Version SOC Term Classification Code Term Level
    19.0 10047065 - Vascular disorders 10020772 Hypertension PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2011-004249-42 Sponsor Protocol Number: Sevicontrol-2 Start Date*: 2011-12-09
    Sponsor Name:IPPMed GmbH
    Full Title: SEVICONTROL-2: Efficacy and Safety of a sequential therapy change from Candesartan 32 mg to the fixed combination of olmesartan 40 mg/amlodipine 10 mg in patients with poorly controlled moderate hy...
    Medical condition: moderate hypertension
    Disease: Version SOC Term Classification Code Term Level
    14.0 10047065 - Vascular disorders 10020772 Hypertension PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2011-004192-37 Sponsor Protocol Number: CRO1749 Start Date*: 2012-04-24
    Sponsor Name:Joint Research Compliance Office, Imperial College
    Full Title: Hellenic Anglo Research into Morning Or Night antihypertensive drug deliverY trial.
    Medical condition: Hypertension
    Disease: Version SOC Term Classification Code Term Level
    17.0 10047065 - Vascular disorders 10020772 Hypertension PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2015-003328-30 Sponsor Protocol Number: CS0866-A-U102 Start Date*: 2015-07-27
    Sponsor Name:Daiichi Sankyo Pharma Development
    Full Title: An Open-Label Study of the Single-Dose Pharmacokinetics of Olmesartan Medoxomil in Pediatric Patients with Hypertension
    Medical condition: Hypertension
    Disease: Version SOC Term Classification Code Term Level
    18.0 10047065 - Vascular disorders 10020772 Hypertension PT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2012-000855-15 Sponsor Protocol Number: CSPP100A2109 Start Date*: 2012-03-14
    Sponsor Name:Novartis Pharma Services AG
    Full Title: An open label, randomized, three period, single-dose, crossover study to determine the bioavailability of 300 mg aliskiren mini-tablets relative to the 300 mg aliskiren market tablet under fasted c...
    Medical condition: Hypertension
    Disease: Version SOC Term Classification Code Term Level
    14.1 10047065 - Vascular disorders 10020772 Hypertension PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2008-007149-30 Sponsor Protocol Number: 4500 Start Date*: 2009-01-14
    Sponsor Name:Cambridge University Hospitals NHS Foundation Trust and University of Cambridge [...]
    1. Cambridge University Hospitals NHS Foundation Trust and University of Cambridge
    2. Cambridge Clinical Trials Unit
    Full Title: Optimal Treatment of Drug Resistant Hypertension
    Medical condition: Hypertension
    Disease: Version SOC Term Classification Code Term Level
    15.0 10047065 - Vascular disorders 10020772 Hypertension PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2013-001421-55 Sponsor Protocol Number: CRFB002GFR02 Start Date*: 2013-06-13
    Sponsor Name:Novartis Pharma S.A.S
    Full Title: An open-label Extended Clinical Protocol of ranibizumab to evaluate Safety and Efficacy in rare VEGF driven ocular diseases.
    Medical condition: Choroidal neovascularization not related to wet Age-related macular degeneration (wAMD), pathologic myopia (PM)or Pseudoxanthoma elasticum (PXE), as well as in Macular Edema (ME) not related to Ret...
    Disease: Version SOC Term Classification Code Term Level
    18.0 10015919 - Eye disorders 10047060 Retina, choroid and vitreous haemorrhages and vascular disorders HLGT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: View results
    EudraCT Number: 2011-004760-29 Sponsor Protocol Number: UIAPB-TAHPS-2011-01 Start Date*: 2012-01-16
    Sponsor Name:Maria Victoria Ruiz Arzalluz
    Full Title: EFFECTIVENESS OF ADMINISTRATION TIMING OF ASPIRIN FROM DAYTIME TO NIGHTIME IN HYPERTENSIVE PATIENTS TREATED WITH LOW DOSE OF ASA IN SECONDARY PREVENTION. - TAHPS
    Medical condition: hypertension
    Disease: Version SOC Term Classification Code Term Level
    14.1 10047065 - Vascular disorders 10020775 Hypertension arterial LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: (No results available)
    EudraCT Number: 2015-003329-32 Sponsor Protocol Number: CS0866-A-U301 Start Date*: 2015-07-28
    Sponsor Name:Daiichi Sankyo Pharma Development
    Full Title: Dose-ranging Study to Evaluate the Safety and Efficacy of Olmesartan Medoxomil in Children and Adolescents With Hypertension
    Medical condition: Hypertension
    Disease: Version SOC Term Classification Code Term Level
    18.0 10047065 - Vascular disorders 10020772 Hypertension PT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2011-004995-13 Sponsor Protocol Number: 38372 Start Date*: 2012-02-09
    Sponsor Name:Erasmus MC
    Full Title: Endovascular renal sympathetic denervation versus spironolactone for treatment-resistant hypertension: a randomized, multicentric study
    Medical condition: Hypertension
    Disease: Version SOC Term Classification Code Term Level
    14.0 10047065 - Vascular disorders 10020772 Hypertension PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2012-001632-64 Sponsor Protocol Number: CLCZ696B2225 Start Date*: 2012-08-08
    Sponsor Name:Novartis Pharma Services AG
    Full Title: An open label, three-period, single sequence study to evaluate the pharmacokinetic drug-drug interaction between LCZ696 and sildenafil in subjects with mild to moderate hypertension
    Medical condition: mild to moderate hypertension
    Disease: Version SOC Term Classification Code Term Level
    14.1 10047065 - Vascular disorders 10020772 Hypertension PT
    Population Age: Adults Gender: Male
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2021-001248-82 Sponsor Protocol Number: ALN-AGT01-002 Start Date*: 2022-10-14
    Sponsor Name:Alnylam Pharmaceuticals, Inc.
    Full Title: A Randomized, Double-blind, Placebo-Controlled, Dose-Ranging Multicenter Study to Evaluate the Efficacy and Safety of ALN-AGT01 in Patients with Mild-to-Moderate Hypertension
    Medical condition: Hypertension
    Disease: Version SOC Term Classification Code Term Level
    20.0 10047065 - Vascular disorders 10020772 Hypertension PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2012-003630-16 Sponsor Protocol Number: GEIDENo.D00112 Start Date*: 2013-04-10
    Sponsor Name:German Heart Centre Munich, Department of
    Full Title: A Randomized, Parallel Group, Double-Blind Study of Ticagrelor Compared with Aspirin for Prevention of Vascular Events in Patients Undergoing Coronary Artery Bypass Graft Operation TiCAB– Ticagrelo...
    Medical condition: Ticagrelor Compared with Aspirin for Prevention of Vascular Events in Patients Undergoing Coronary Artery Bypass Graft Operation
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004866 10003601 Atherosclerosis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) AT (Prematurely Ended)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 5  6  7  8  9  10  11  12  13  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Mon Jun 02 07:35:24 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA